XML 23 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities:    
Net income (loss) $ (18,873,758) $ 25,530,961
Adjustments to reconcile net income (loss) to net cash flows used in operating activities:    
Depreciation and amortization 2,176,679 822,489
Gain on sale of property, plant and equipment (212,831)
Stock based compensation 1,282,757 1,605,949
Provision for doubtful accounts receivable (39,502) 9,990
Provision for doubtful lease receivable 140,448
Gain on extinguishment of debt (10,000)
Change in fair value of contingent consideration promissory notes and earn-out agreements (516,970) (3,732,789)
Change in fair value of warrant derivative liability (6,726,638) (36,664,907)
Gain of extinguishment of warrant derivative liabilities (3,624,794)
Warrant modification expense 295,780
Provision for inventory obsolescence 1,574,453 1,954,738
Increase (decrease) in:    
Accounts receivable – trade 722,498 (29,838)
Accounts receivable – other (including related party) (2,195,157) (693,992)
Inventories 1,245,677 (1,431,080)
Prepaid expenses 1,293,080 (3,839,458)
Operating lease right of use assets 328,772 180,497
Other assets (3,048,382) (738,466)
Accounts payable 4,709,030 (1,907,608)
Accrued expenses (112,896) 166,874
Income taxes payable 6,270 (5,331)
Operating lease obligations (328,772) (195,884)
Contract liabilities 3,619,651 856,967
Net cash used in operating activities (18,580,385) (17,825,108)
Cash Flows from Investing Activities:    
Purchases of property, plant and equipment (2,068,508) (6,428,225)
Proceeds from sale of property, plant and equipment 609,559
Purchases of intangible assets (116,990) (1,189,132)
Proceeds from sale of intangible assets 18,975
Cash paid for acquisition of Medical Billing Company (1,026,508)
Cash paid for acquisition of Medical Billing Company (2,270,000)
Cash paid for acquisition of Medical Billing Company (1,153,627)
Cash paid for asset acquisition of Medical Billing Company (230,000)
Cash paid for acquisition of TicketSmarter (8,615,514)
Collection of notes receivable 405,000
Net cash used in investing activities (2,940,591) (19,124,379)
Cash Flows from Financing Activities:    
Proceeds from issuance of common stock upon exercise of pre-funded warrants 53,224,000
Net proceeds from sale of common stock in registered direct offerings 13,346,600
Repurchase and cancellation of common stock (4,026,523) (1,975,079)
Distribution to noncontrolling interest in consolidated subsidiary (15,692)
Principal payment on contingent consideration promissory notes (527,402)
Proceeds from issuance of Series A & B convertible redeemable preferred shares, net of issuance costs 13,365,000
Redemption of Series A & B convertible redeemable preferred shares (15,750,000)
Net cash provided by (used in) financing activities (6,954,617) 64,595,521
Net increase (decrease) in cash and cash equivalents (28,475,593) 27,646,034
Cash, cash equivalents, beginning of year 32,007,792 4,361,758
Cash, cash equivalents, end of year 3,532,199 32,007,792
Supplemental disclosures of cash flow information:    
Cash payments for interest 49,070
Cash payments for income taxes 8,730 1,224
Supplemental disclosures of non-cash investing and financing activities:    
Restricted common stock grant 61 43
Restricted common stock forfeitures 3
Issuance of contingent consideration earn-out agreement for business acquisitions 750,000 3,700,000
Issuance of contingent consideration promissory note for business acquisitions 1,000,000
Issuance of contingent consideration promissory note for asset acquisitions 105,000
Assets acquired in business acquisitions 190,631 6,324,189
Identifiable intangible assets acquired in business acquisitions 6,800,000
Goodwill acquired in business acquisitions 2,100,000 9,931,547
Liabilities assumed in business acquisitions 387,005 5,453,353
ROU and lease liability recorded on extension of lease 42,403
Common stock issued as consideration for business acquisitions 990,360
Amounts allocated to initial measurement of warrant derivative liabilities in connection to the warrants and pre-funded warrants 51,216,058
Issuance of common stock through warrant exchange agreement 4,495,500
Cancellation of treasury stock $ 2,157,225